Every 424B that Veraxa Biotech AG (VRXA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VRXA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRXA filings page.
Veraxa Biotech AG (VRXA) filed a prospectus supplement updating its Form F-1 to cover the issuance of up to 19,436,739 Ordinary Shares upon exercise of warrants at US$11.50 per share and the potential resale of up to 6,786,739 Private Warrants and up to 120,295,385 Ordinary Shares by selling securityholders.
The company’s Ordinary Shares trade on the Nasdaq Global Market under “VRXA” at $1.53 and its Warrants on the Nasdaq Capital Market under “VRXAW” at $0.08 as of September 3, 2026. Veraxa will receive cash only if warrants are exercised for cash. Veraxa also highlights its status as an emerging growth company and foreign private issuer, which allows reduced U.S. reporting and different corporate governance practices. Separately, Veraxa appointed Raju Willener as Chief Financial Officer and principal financial and accounting officer, bringing more than three decades of global finance and capital markets experience.
Veraxa Biotech AG (VRXA) filed a prospectus supplement for the resale, from time to time, of up to 25,000,000 ordinary shares by Lincoln Park Capital Fund, LLC under an existing purchase agreement. Veraxa may sell Ordinary Shares to Lincoln Park at its discretion and could receive up to $50,000,000 in gross proceeds from such sales, but will receive no proceeds from Lincoln Park’s resale of the registered shares.
The company’s Ordinary Shares and warrants trade on Nasdaq under the symbols VRXA and VRXAW, which closed at $1.53 and $0.08 on September 3, 2026. Veraxa is an emerging growth company and a foreign private issuer, and follows home-country corporate governance practices that may provide fewer protections than Nasdaq standards for U.S. domestic companies.
Separately, Veraxa appointed Raju Willener as Chief Financial Officer and principal financial and accounting officer, effective immediately. He brings more than three decades of international finance and capital markets experience, including oversight of investment portfolios exceeding CHF 30 billion in assets under management, to support the company’s antibody-based cancer therapy pipeline and BiTAC® platform.
Veraxa Biotech AG is registering up to 19,436,739 Ordinary Shares issuable upon exercise of outstanding Public and Private Warrants at $11.50 per share. A further 120,295,385 Ordinary Shares and 6,786,739 Private Warrants may be resold from time to time by selling securityholders.
The company will receive no proceeds from these resales and only cash if Warrants are exercised, while holders may elect cashless exercise for Private Warrants. On August 7, 2026, Ordinary Shares closed at $1.99 and Warrants at $0.096, which the company believes makes warrant exercise unlikely while the price is below $11.50.
There were 141,407,813 Ordinary Shares outstanding as of the prospectus date. Veraxa is an oncology-focused biotech with no approved products, an accumulated deficit of CHF 66.6 million, and discloses it is an emerging growth company and a foreign private issuer using home-country Swiss corporate governance practices, which may offer shareholders fewer protections than U.S. domestic issuers.
Veraxa Biotech AG, a Swiss oncology-focused biotechnology company and emerging growth foreign private issuer, has filed a prospectus for the resale of up to 25,000,000 ordinary shares by Lincoln Park Capital Fund under a previously agreed purchase arrangement. These shares include 340,910 commitment shares already issued and up to 24,659,090 shares Veraxa may sell to Lincoln Park over a 24‑month term, tied to a total purchase commitment of up to $50,000,000. Veraxa will not receive proceeds from Lincoln Park’s resale of registered shares but may receive cash from future primary share sales to Lincoln Park under the Purchase Agreement, subject to a Beneficial Ownership Limitation of 4.99%, adjustable to 9.99%. Ordinary shares trade on Nasdaq Global Market under “VRXA” and warrants on Nasdaq Capital Market under “VRXAW.” Assuming all 25,000,000 shares are issued, ordinary shares outstanding would be 166,066,903. Veraxa emphasizes significant operating losses, need for substantial additional capital, clinical and regulatory risks for its oncology pipeline, and governance and disclosure differences arising from its Swiss domicile and foreign private issuer status.